Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Other Working Capital Changes (2016 - 2025)

Regenxbio has reported Other Working Capital Changes over the past 12 years, most recently at -$4.5 million for Q4 2025.

  • Quarterly results put Other Working Capital Changes at -$4.5 million for Q4 2025, down 134.32% from a year ago — trailing twelve months through Dec 2025 was -$658000.0 (up 87.93% YoY), and the annual figure for FY2025 was -$658000.0, up 87.93%.
  • Other Working Capital Changes for Q4 2025 was -$4.5 million at Regenxbio, down from $2.2 million in the prior quarter.
  • Over the last five years, Other Working Capital Changes for RGNX hit a ceiling of $39.8 million in Q1 2025 and a floor of -$38.1 million in Q2 2025.
  • Median Other Working Capital Changes over the past 5 years was -$697500.0 (2021), compared with a mean of -$668700.0.
  • Biggest five-year swings in Other Working Capital Changes: skyrocketed 972.02% in 2022 and later tumbled 1018.5% in 2024.
  • Regenxbio's Other Working Capital Changes stood at -$4.2 million in 2021, then plummeted by 82.5% to -$7.7 million in 2022, then skyrocketed by 97.75% to -$173000.0 in 2023, then tumbled by 1018.5% to -$1.9 million in 2024, then plummeted by 134.32% to -$4.5 million in 2025.
  • The last three reported values for Other Working Capital Changes were -$4.5 million (Q4 2025), $2.2 million (Q3 2025), and -$38.1 million (Q2 2025) per Business Quant data.